Sangamo Therapeutics, Inc (SGMOQ): who owns it and who trades it
As of Nov 16, 2026, SGMOQ insiders reported 2 open-market sales worth $107K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Nathalie Dubois-Stringfellow (Vice president), with $89.9K.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, SGMOQ insiders reported $0 of open-market purchases and $107K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | Gregory D Davis | Head of Research & Techn | Sale | 69,827 | $0.25 | $17.5K | Form 4 |
| Apr 21, 2026 | Nathalie Dubois-Stringfellow | Vice president | Sale | 345,942 | $0.26 | $89.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Nathalie Dubois-Stringfellow | SVP-CHIEF DEVELOPMENT OFFICER | – | $89.9K | Apr 21, 2026 |
| Gregory D Davis | Head of Research & Technology | – | $17.5K | Apr 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SGMOQ short interest
8.35M SGMOQ shares are sold short. Over the last 9 reports the number of shares short went down 47%.
As of Oct 30, 2026, 8.35M SGMOQ shares were sold short, down 2.1% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 4.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.35M | – | -2% | 1.71M | 4.9 |
| Oct 15, 2026 | 8.52M | – | -8% | 3.35M | 2.5 |
| Sep 30, 2026 | 9.31M | 2.25% | -13% | 2.79M | 3.3 |
| Sep 15, 2026 | 10.72M | 2.59% | +3% | 3.32M | 3.2 |
| Aug 31, 2026 | 10.43M | 2.52% | +5% | 6.19M | 1.7 |
| Aug 14, 2026 | 9.94M | 2.40% | -4% | 8.65M | 1.1 |
| Jul 31, 2026 | 10.34M | 2.50% | -1% | 4.54M | 2.3 |
| Jul 15, 2026 | 10.48M | 2.53% | -34% | 7.95M | 1.3 |
| Jun 30, 2026 | 15.90M | 3.84% | -36% | 24.28M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Sangamo Therapeutics company events
Sangamo Therapeutics filed 16 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing, bankruptcy). The latest was on Oct 27, 2026.
- Oct 27, 2026AnnouncementShared information with investors. Filing
- Oct 16, 2026AnnouncementShared information with investors. Filing
- Sep 21, 2026BankruptcyThe information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Filing
- Sep 8, 2026BankruptcyThe information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Filing
- Aug 28, 2026BankruptcyOf this Current Report on Form 8-K under the heading “PTC Asset Purchase Agreement” is incorporated herein by reference. Filing
- Aug 13, 2026AnnouncementAs previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware, thereby commencing a Chapter 11 case for the Company. Filing
- Aug 12, 2026AnnouncementShared information with investors. Filing
- Jul 20, 2026BankruptcyAs previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition (Case No. 26-10989) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such case, the “Case”). Filing
- Jul 1, 2026AuditorChange in Registrant’s Certifying Accountant. Filing
- Jun 23, 2026BankruptcyOf this Current Report on Form 8-K under the heading “Stalking Horse Asset Purchase Agreements” is incorporated herein by reference. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Apr 29, 2026ListingGot a notice from its stock exchange about its listing, or moved its listing. Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Feb 4, 2026AgreementSangamo Therapeutics, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of 35,190,292 shares of the Company’s common stock, par value $0.01 per… Filing
- Feb 3, 2026AnnouncementSangamo Therapeutics, Inc. announced the presentation of clinical data from its registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease, in four clinical and nonclinical platform and… Filing
- Feb 3, 2026LeadershipThe employment of Prathyusha Duraibabu, the Company’s principal financial officer, terminated. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Sangamo Therapeutics financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SGMOQ in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 9.8% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 9.8% |
Questions about Sangamo Therapeutics, Inc (SGMOQ) stock
Are SGMOQ insiders buying or selling?
In the last 12 months, SGMOQ insiders reported no open-market purchases and 2 sales worth $107K. The latest trade was on Apr 22, 2026. See every trade.
What is the short interest in SGMOQ?
As of Oct 30, 2026, 8.35M SGMOQ shares were sold short, down 2.1% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 4.9 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.